SLC39A6 Specific Neutra™ Antibody Products

SLC39A6 (solute carrier family 39 member 6), is also commonly known as Zinc transporter ZIP6 (ZIP6) and LIV-1. It is initially recognized as an estrogen-induced gene in breast cancer and then has been reported to be associated with multiple other malignancies, including prostate, cervical, liver, and pancreatic cancers. It is a promising target of monoclonal antibodies for related cancer research.

Its Gene ID: 25800, UniProtKB ID: Q13433, and OMIM ID: 608731.

Functions of SLC39A6

Zinc plays an essential role in various biological processes of organisms, including gene expression, growth, development, enzyme function, immune function, etc., as well as cancer biology. SLC39A6 is a subfamily member of zinc transporters, which is involved in maintaining the intracellular homeostasis of zinc. SLC39A6 possesses a histidine-rich transcriptional domain that binds to zinc, transferring zinc into the cytosol via the membrane and contributing to its transport into the cell.

Fig.1 Predicted subcellular localization of the identified ZIP transporters within human and rodent β-cells.¹

SLC39A6 is demonstrated to be involved with a wide range of enzymes related to the metabolism of nucleic acid, protein, lipid, and carbohydrate, as well as gene transcription, development, and differentiation. Previous findings indicate that expression levels and functions of SLC39A6 vary in different types of malignancies, depending on the types and contexts of tumors. In breast cancer, SLC39A6 is reported to participate in lymph node involvement and might take part in metastasis, while in liver cancer high expression of SLC39A6 is closely interrelated with poor overall survival.

Fig.2 Summary of current knowledge of ZIP6, ZIP10, and ZIP7 contribution to tamoxifen-resistant phenotypes in breast cancer.²

SLC39A6 as a Target for Antibody in Cancer Immunotherapy

Since SLC39A6 aids in the influx of zinc into the cytosol and plays critical roles in cancer cell proliferation and migration, it has been considered an available candidate for both antibody-drug conjugate treatment and tumor markers. Several antibodies have been designed and studied targeting SLC39A6.

It is reported that a camelid monoclonal nanobody against SLC39A6 is selected to detect and block the SLC39A6, which exhibits hallmark characteristics of an antitumor agent, inhibiting tumor cell proliferation and providing a potential candidate for the development of therapeutics.

Creative Biolabs offers recombinant anti-SLC39A6 (N-terminus) antibody products. These antibodies are recombinantly expressed and could be used for WB and ELISA. Customization of SLC39A6-based bispecific antibodies is also available for you here.

REFERENCES

1. Lawson, Rebecca, Wolfgang Maret, and Christer Hogstrand. "Expression of the ZIP/SLC39A transporters in β-cells: a systematic review and integration of multiple datasets." BMC genomics 18 (2017): 1-13.
2. Jones, Samuel, et al. "The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer." Exploration of targeted anti-tumor therapy 3.2 (2022): 224.